HEADER ISOMERASE 25-JAN-07 2OOH TITLE CRYSTAL STRUCTURE OF MIF BOUND TO A NOVEL INHIBITOR, OXIM-11 COMPND MOL_ID: 1; COMPND 2 MOLECULE: MACROPHAGE MIGRATION INHIBITORY FACTOR; COMPND 3 CHAIN: A, B, C; COMPND 4 SYNONYM: MIF, PHENYLPYRUVATE TAUTOMERASE, GLYCOSYLATION-INHIBITING COMPND 5 FACTOR, GIF, (EC 5.3.2.1); COMPND 6 EC: 5.3.2.1; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 GENE: MIF; SOURCE 6 EXPRESSION_SYSTEM: ESCHERICHIA COLI BL21(DE3); SOURCE 7 EXPRESSION_SYSTEM_TAXID: 469008; SOURCE 8 EXPRESSION_SYSTEM_STRAIN: BL21(DE3); SOURCE 9 EXPRESSION_SYSTEM_VECTOR_TYPE: PLASMID; SOURCE 10 EXPRESSION_SYSTEM_PLASMID: PET11B KEYWDS ALTERNATIVE LIGAND-BINDING MODES, ISOMERASE EXPDTA X-RAY DIFFRACTION AUTHOR G.V.CRICHLOW,Y.AL-ABED,E.LOLIS REVDAT 5 18-OCT-17 2OOH 1 REMARK REVDAT 4 13-JUL-11 2OOH 1 VERSN REVDAT 3 24-FEB-09 2OOH 1 VERSN REVDAT 2 12-FEB-08 2OOH 1 JRNL REVDAT 1 05-JUN-07 2OOH 0 JRNL AUTH G.V.CRICHLOW,K.F.CHENG,D.DABIDEEN,M.OCHANI,B.ALJABARI, JRNL AUTH 2 V.A.PAVLOV,E.J.MILLER,E.LOLIS,Y.AL-ABED JRNL TITL ALTERNATIVE CHEMICAL MODIFICATIONS REVERSE THE BINDING JRNL TITL 2 ORIENTATION OF A PHARMACOPHORE SCAFFOLD IN THE ACTIVE SITE JRNL TITL 3 OF MACROPHAGE MIGRATION INHIBITORY FACTOR. JRNL REF J.BIOL.CHEM. V. 282 23089 2007 JRNL REFN ISSN 0021-9258 JRNL PMID 17526494 JRNL DOI 10.1074/JBC.M701825200 REMARK 2 REMARK 2 RESOLUTION. 1.85 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : CNS REMARK 3 AUTHORS : BRUNGER,ADAMS,CLORE,DELANO,GROS,GROSSE- REMARK 3 : KUNSTLEVE,JIANG,KUSZEWSKI,NILGES,PANNU, REMARK 3 : READ,RICE,SIMONSON,WARREN REMARK 3 REMARK 3 REFINEMENT TARGET : ENGH & HUBER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.85 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 110.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 0.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : 95.1 REMARK 3 NUMBER OF REFLECTIONS : 44612 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT, UNTIL MOST OF THE REMARK 3 MODEL WAS COMPLETED, THEN ALL REMARK 3 OBSERVED DATA WERE USED IN REMARK 3 SOME OF THE LATER REFINEMENT REMARK 3 ROUNDS. (R-FREE VALUE QUOTED REMARK 3 IS THAT OBTAINED BEFORE REMARK 3 REFINEMENT WAS PERFORMED REMARK 3 AGAINST ALL DATA). REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING SET) : 0.191 REMARK 3 FREE R VALUE : 0.218 REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : 2228 REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 2586 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 88 REMARK 3 SOLVENT ATOMS : 305 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : 22.76 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM SIGMAA (A) : NULL REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : NULL REMARK 3 BOND ANGLES (DEGREES) : NULL REMARK 3 DIHEDRAL ANGLES (DEGREES) : NULL REMARK 3 IMPROPER ANGLES (DEGREES) : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : ISOTROPIC REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 BULK SOLVENT MODELING. REMARK 3 METHOD USED : NULL REMARK 3 KSOL : NULL REMARK 3 BSOL : NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: OXIM-11 MOLECULES WERE MODELLED WITH REMARK 3 PARTIAL OCCUPANCIES. GLYCEROL MOLECULES MODELLED IN THE SAME REMARK 3 ACTIVE SITES AS OXIM-11 HAVE OCCUPANCIES WERE MODLLED AS HAVING REMARK 3 OCCUPANCIES EQUAL TO 1-(OXIM-11 OCCUPANCY FOR THAT ACTIVE SITE). REMARK 3 THE RATIO OF OXIM-11 TO GLYCEROL OCCUPANCY FOR EACH ACTIVE SITE REMARK 3 WAS DETERMINED BY OCCUPANCY REFINEMENT IN CNS REMARK 4 REMARK 4 2OOH COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY RCSB ON 22-FEB-07. REMARK 100 THE DEPOSITION ID IS D_1000041389. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 17-JAN-06 REMARK 200 TEMPERATURE (KELVIN) : 93 REMARK 200 PH : 7.5 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : ROTATING ANODE REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : RIGAKU REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 1.5418 REMARK 200 MONOCHROMATOR : GRAPHITE REMARK 200 OPTICS : MIRRORS REMARK 200 REMARK 200 DETECTOR TYPE : IMAGE PLATE REMARK 200 DETECTOR MANUFACTURER : RIGAKU RAXIS IV REMARK 200 INTENSITY-INTEGRATION SOFTWARE : DENZO, HKL-2000 REMARK 200 DATA SCALING SOFTWARE : SCALEPACK, HKL-2000 REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 46128 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.850 REMARK 200 RESOLUTION RANGE LOW (A) : 110.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : -3.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 98.2 REMARK 200 DATA REDUNDANCY : 4.600 REMARK 200 R MERGE (I) : 0.06100 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 20.1000 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.85 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.92 REMARK 200 COMPLETENESS FOR SHELL (%) : 96.0 REMARK 200 DATA REDUNDANCY IN SHELL : 4.00 REMARK 200 R MERGE FOR SHELL (I) : 0.35000 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: AMORE REMARK 200 STARTING MODEL: PDB ENTRY 1LJT REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 66.45 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.67 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: 50% SATURATED AMMONIUM SULFATE, 4% REMARK 280 ISOPROPANOL, 0.1 M TRIS(HYDROXYMETHYL)AMINOMETHANE,MIXED WITH REMARK 280 PROTEIN:INHIBITOR COMPLEX IN A 1:1 RATIO, PH 7.5, VAPOR REMARK 280 DIFFUSION, HANGING DROP, TEMPERATURE 296K REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 31 2 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -Y,X-Y,Z+1/3 REMARK 290 3555 -X+Y,-X,Z+2/3 REMARK 290 4555 Y,X,-Z REMARK 290 5555 X-Y,-Y,-Z+2/3 REMARK 290 6555 -X,-X+Y,-Z+1/3 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 2 0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 34.36400 REMARK 290 SMTRY1 3 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 3 -0.866025 -0.500000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 1.000000 68.72800 REMARK 290 SMTRY1 4 -0.500000 0.866025 0.000000 0.00000 REMARK 290 SMTRY2 4 0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 5 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 5 0.000000 0.000000 -1.000000 68.72800 REMARK 290 SMTRY1 6 -0.500000 -0.866025 0.000000 0.00000 REMARK 290 SMTRY2 6 -0.866025 0.500000 0.000000 0.00000 REMARK 290 SMTRY3 6 0.000000 0.000000 -1.000000 34.36400 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 300 REMARK: THE ASYMMETRIC UNIT CONTAINS ONE HOMOTRIMER OF MIF, WHICH REMARK 300 IS PRESUMED TO BE THRE BIOLOGICAL UNIT. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA,PQS REMARK 350 TOTAL BURIED SURFACE AREA: 9760 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 12820 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -136.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A, B, C REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 ARG A 88 NE CZ NH1 NH2 REMARK 470 ARG B 11 CD NE CZ NH1 NH2 REMARK 470 LYS B 66 CE NZ REMARK 470 LYS B 77 CE NZ REMARK 470 LYS C 66 CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 SER A 111 -158.98 -145.27 REMARK 500 SER B 111 -158.81 -147.44 REMARK 500 ASN C 109 74.50 37.93 REMARK 500 SER C 111 -163.24 -170.38 REMARK 500 REMARK 500 REMARK: NULL REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 901 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 905 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 906 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC4 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 907 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC5 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 A 908 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC6 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 902 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC7 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 B 904 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC8 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE SO4 C 903 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC9 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE OX3 B 200 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE OX3 C 200 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL C 701 REMARK 800 REMARK 800 SITE_IDENTIFIER: BC3 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE GOL C 702 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2OOW RELATED DB: PDB REMARK 900 RELATED ID: 2OOZ RELATED DB: PDB DBREF 2OOH A 1 114 UNP P14174 MIF_HUMAN 1 114 DBREF 2OOH B 1 114 UNP P14174 MIF_HUMAN 1 114 DBREF 2OOH C 1 114 UNP P14174 MIF_HUMAN 1 114 SEQRES 1 A 114 PRO MET PHE ILE VAL ASN THR ASN VAL PRO ARG ALA SER SEQRES 2 A 114 VAL PRO ASP GLY PHE LEU SER GLU LEU THR GLN GLN LEU SEQRES 3 A 114 ALA GLN ALA THR GLY LYS PRO PRO GLN TYR ILE ALA VAL SEQRES 4 A 114 HIS VAL VAL PRO ASP GLN LEU MET ALA PHE GLY GLY SER SEQRES 5 A 114 SER GLU PRO CYS ALA LEU CYS SER LEU HIS SER ILE GLY SEQRES 6 A 114 LYS ILE GLY GLY ALA GLN ASN ARG SER TYR SER LYS LEU SEQRES 7 A 114 LEU CYS GLY LEU LEU ALA GLU ARG LEU ARG ILE SER PRO SEQRES 8 A 114 ASP ARG VAL TYR ILE ASN TYR TYR ASP MET ASN ALA ALA SEQRES 9 A 114 ASN VAL GLY TRP ASN ASN SER THR PHE ALA SEQRES 1 B 114 PRO MET PHE ILE VAL ASN THR ASN VAL PRO ARG ALA SER SEQRES 2 B 114 VAL PRO ASP GLY PHE LEU SER GLU LEU THR GLN GLN LEU SEQRES 3 B 114 ALA GLN ALA THR GLY LYS PRO PRO GLN TYR ILE ALA VAL SEQRES 4 B 114 HIS VAL VAL PRO ASP GLN LEU MET ALA PHE GLY GLY SER SEQRES 5 B 114 SER GLU PRO CYS ALA LEU CYS SER LEU HIS SER ILE GLY SEQRES 6 B 114 LYS ILE GLY GLY ALA GLN ASN ARG SER TYR SER LYS LEU SEQRES 7 B 114 LEU CYS GLY LEU LEU ALA GLU ARG LEU ARG ILE SER PRO SEQRES 8 B 114 ASP ARG VAL TYR ILE ASN TYR TYR ASP MET ASN ALA ALA SEQRES 9 B 114 ASN VAL GLY TRP ASN ASN SER THR PHE ALA SEQRES 1 C 114 PRO MET PHE ILE VAL ASN THR ASN VAL PRO ARG ALA SER SEQRES 2 C 114 VAL PRO ASP GLY PHE LEU SER GLU LEU THR GLN GLN LEU SEQRES 3 C 114 ALA GLN ALA THR GLY LYS PRO PRO GLN TYR ILE ALA VAL SEQRES 4 C 114 HIS VAL VAL PRO ASP GLN LEU MET ALA PHE GLY GLY SER SEQRES 5 C 114 SER GLU PRO CYS ALA LEU CYS SER LEU HIS SER ILE GLY SEQRES 6 C 114 LYS ILE GLY GLY ALA GLN ASN ARG SER TYR SER LYS LEU SEQRES 7 C 114 LEU CYS GLY LEU LEU ALA GLU ARG LEU ARG ILE SER PRO SEQRES 8 C 114 ASP ARG VAL TYR ILE ASN TYR TYR ASP MET ASN ALA ALA SEQRES 9 C 114 ASN VAL GLY TRP ASN ASN SER THR PHE ALA HET SO4 A 901 5 HET SO4 A 905 5 HET SO4 A 906 5 HET SO4 A 907 5 HET SO4 A 908 5 HET SO4 B 902 5 HET SO4 B 904 5 HET OX3 B 200 18 HET SO4 C 903 5 HET OX3 C 200 18 HET GOL C 701 6 HET GOL C 702 6 HETNAM SO4 SULFATE ION HETNAM OX3 4-HYDROXYBENZALDEHYDE O-(CYCLOHEXYLCARBONYL)OXIME HETNAM GOL GLYCEROL HETSYN GOL GLYCERIN; PROPANE-1,2,3-TRIOL FORMUL 4 SO4 8(O4 S 2-) FORMUL 11 OX3 2(C14 H17 N O3) FORMUL 14 GOL 2(C3 H8 O3) FORMUL 16 HOH *305(H2 O) HELIX 1 1 PRO A 10 VAL A 14 5 5 HELIX 2 2 GLY A 17 GLY A 31 1 15 HELIX 3 3 PRO A 33 TYR A 36 5 4 HELIX 4 4 GLY A 68 ARG A 88 1 21 HELIX 5 5 SER A 90 ASP A 92 5 3 HELIX 6 6 ASN A 102 ALA A 104 5 3 HELIX 7 7 PRO B 10 VAL B 14 5 5 HELIX 8 8 GLY B 17 GLY B 31 1 15 HELIX 9 9 PRO B 33 TYR B 36 5 4 HELIX 10 10 GLY B 68 ARG B 88 1 21 HELIX 11 11 SER B 90 ASP B 92 5 3 HELIX 12 12 ASN B 102 ALA B 104 5 3 HELIX 13 13 PRO C 10 VAL C 14 5 5 HELIX 14 14 GLY C 17 GLY C 31 1 15 HELIX 15 15 PRO C 33 TYR C 36 5 4 HELIX 16 16 GLY C 68 ARG C 88 1 21 HELIX 17 17 SER C 90 ASP C 92 5 3 HELIX 18 18 ASN C 102 ALA C 104 5 3 SHEET 1 A 7 LEU B 46 PHE B 49 0 SHEET 2 A 7 ALA A 38 VAL A 42 -1 N VAL A 39 O ALA B 48 SHEET 3 A 7 MET A 2 THR A 7 1 N VAL A 5 O VAL A 42 SHEET 4 A 7 ALA A 57 SER A 63 -1 O HIS A 62 N MET A 2 SHEET 5 A 7 VAL A 94 ASP A 100 1 O TYR A 95 N CYS A 59 SHEET 6 A 7 VAL C 106 TRP C 108 -1 O GLY C 107 N ILE A 96 SHEET 7 A 7 SER C 111 THR C 112 -1 O SER C 111 N TRP C 108 SHEET 1 B 7 LEU A 46 PHE A 49 0 SHEET 2 B 7 ALA C 38 VAL C 42 -1 O VAL C 41 N LEU A 46 SHEET 3 B 7 MET C 2 THR C 7 1 N VAL C 5 O VAL C 42 SHEET 4 B 7 ALA C 57 SER C 63 -1 O HIS C 62 N MET C 2 SHEET 5 B 7 VAL C 94 ASP C 100 1 O TYR C 95 N CYS C 59 SHEET 6 B 7 VAL B 106 TRP B 108 -1 N GLY B 107 O ILE C 96 SHEET 7 B 7 SER B 111 THR B 112 -1 O SER B 111 N TRP B 108 SHEET 1 C 7 SER A 111 THR A 112 0 SHEET 2 C 7 VAL A 106 TRP A 108 -1 N TRP A 108 O SER A 111 SHEET 3 C 7 VAL B 94 ASP B 100 -1 O ILE B 96 N GLY A 107 SHEET 4 C 7 ALA B 57 SER B 63 1 N CYS B 59 O TYR B 95 SHEET 5 C 7 MET B 2 THR B 7 -1 N MET B 2 O HIS B 62 SHEET 6 C 7 ALA B 38 VAL B 42 1 O VAL B 42 N VAL B 5 SHEET 7 C 7 LEU C 46 PHE C 49 -1 O LEU C 46 N VAL B 41 SITE 1 AC1 5 GLY A 68 GLY A 69 ALA A 70 GLN A 71 SITE 2 AC1 5 HOH A 400 SITE 1 AC2 6 ARG A 73 HOH A 232 HOH A 422 PRO B 15 SITE 2 AC2 6 ASP B 16 HOH C 453 SITE 1 AC3 5 PRO A 15 ASP A 16 HOH A 219 HOH A 451 SITE 2 AC3 5 SER B 53 SITE 1 AC4 5 ALA A 70 ARG A 73 HOH A 228 HOH A 495 SITE 2 AC4 5 HOH B 329 SITE 1 AC5 7 HIS A 62 TYR A 99 HOH A 462 HIS B 62 SITE 2 AC5 7 TYR B 99 HIS C 62 TYR C 99 SITE 1 AC6 5 GLY B 68 GLY B 69 ALA B 70 GLN B 71 SITE 2 AC6 5 HOH B 458 SITE 1 AC7 7 LYS A 77 ASP B 16 GLY B 17 PHE B 18 SITE 2 AC7 7 LEU B 19 SER B 20 HOH B 368 SITE 1 AC8 4 GLY C 68 GLY C 69 ALA C 70 GLN C 71 SITE 1 AC9 15 HOH A 424 PRO B 1 MET B 2 LYS B 32 SITE 2 AC9 15 TYR B 36 HIS B 62 SER B 63 ILE B 64 SITE 3 AC9 15 ASP B 92 MET B 101 VAL B 106 PHE B 113 SITE 4 AC9 15 HOH B 283 TYR C 95 ASN C 97 SITE 1 BC1 12 TYR A 95 ASN A 97 PRO C 1 MET C 2 SITE 2 BC1 12 LYS C 32 TYR C 36 HIS C 62 SER C 63 SITE 3 BC1 12 ILE C 64 MET C 101 VAL C 106 PHE C 113 SITE 1 BC2 6 PRO B 1 HIS B 62 SER B 63 TYR C 95 SITE 2 BC2 6 ASN C 97 HOH C 204 SITE 1 BC3 6 ASN A 97 PRO C 1 MET C 2 HIS C 62 SITE 2 BC3 6 SER C 63 ILE C 64 CRYST1 95.595 95.595 103.092 90.00 90.00 120.00 P 31 2 1 18 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.010460 0.006039 0.000000 0.00000 SCALE2 0.000000 0.012078 0.000000 0.00000 SCALE3 0.000000 0.000000 0.009700 0.00000 MASTER 322 0 12 18 21 0 26 6 0 0 0 27 END